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Abstract
Background: Cannabinoid 1 (CB1) receptor antagonists exhibit pharmacological properties favorable for the
treatment of obesity and other related metabolic disorders. CE-178253 (1-[7-(2-Chlorophenyl)-8-(4-chlorophenyl)-
2-methylpyrazolo[1,5-a]-[1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid hydrochloride) is a recently
discovered selective centrally-acting CB1 receptor antagonist. Despite a large body of knowledge on cannabinoid
receptor antagonists little data exist on the quantitative pharmacology of this therapeutic class of drugs. The
purpose of the current studies was to evaluate the quantitative pharmacology and concentration/effect
relationships of CE-178253 based on unbound plasma concentration and in vitro pharmacology data in different
in vivo preclinical models of FI and energy expenditure.
Results: In vitro, CE-178253 exhibits sub-nanomolar potency at human CB1 receptors in both binding (Ki = 0.33
nM) and functional assays (Ki = 0.07 nM). CE-178253 has low affinity (Ki > 10,000 nM) for human CB2 receptors.
In vivo, CE-178253 exhibits concentration-dependent anorectic activity in both fast-induced re-feeding and
spontaneous nocturnal feeding FI models. As measured by indirect calorimetry, CE-178253 acutely stimulates
energy expenditure by greater than 30% in rats and shifts substrate oxidation from carbohydrate to fat as indicated
by a decrease the respiratory quotient from 0.85 to 0.75. Determination of the concentration-effect relationships
and ex vivo receptor occupancy in efficacy models of energy intake and expenditure suggest that a greater than a
2-fold coverage of the Ki (50-75% receptor occupancy) is required for maximum efficacy. Finally, in two preclinical
models of obesity, CE-178253 dose-dependently promotes weight loss in diet-induced obese rats and mice.
Conclusions: We have combined quantitative pharmacology and ex vivo CB1 receptor occupancy data to assess
concentration/effect relationships in food intake, energy expenditure and weight loss studies. Quantitative
pharmacology studies provide a strong a foundation for establishing and improving confidence in mechanism as
well as aiding in the progression of compounds from preclinical pharmacology to clinical development.
Background
Cannabinoid receptors are members of the G protein-
coupled receptor superfamily [1]. Two cannabinoid
receptors, CB1 and CB2, have been pharmacologically
identified. CB1 and CB2 receptors modulate several
downstream signaling pathways including the inhibition
of intracellular cyclic AMP accumulation, stimulation of
MAP kinase activity and modulation of potassium and
calcium channel activities [1]. The fatty acid derivative
anandamide was isolated from porcine brain tissue,
found to compete for cannabinoid receptor binding and
identified as the first endogenous cannabinoid [2]. Other
endogenous ligands have been identified, including 2-
arachidonylglycerol [3] and archidonylglycerol ether [4].
Anandamide administration leads to a number of phar-
macological effects that are similar in nature to THC
[5]. As components of the endocannabinoid system have
been identified, pharmacological opportunities to
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been increasingly explored.
The observation that CB1 receptor antagonists may be
useful as drugs for the management of obesity and meta-
bolic disease was made in 1997 when Aronne and collea-
gues reported that SR141716A (rimonabant) selectively
inhibited sucrose consumption relative to normal chow
consumption in male rats [6]. Since this observation,
rimonabant has been used extensively in preclinical and
clinical settings to define the role of the endocannabinoid
system in appetitive (and other) behaviors [7], and more
broadly to understand the role of the endocannabinoid
system in regulation of energy balance [8-10]. It was
hoped that brain-penetrant CB1 R antagonists might pro-
vide effective therapeutic options for the management of
metabolic disorders, such as obesity. Several CB1 receptor
inverse agonists/antagonists were recently withdrawn
from the market or clinical development including the
diarylpyrazole rimonabant or SR141716A [11], the acyclic
amide taranabant [12], CP-945598 [13], and CE-178253,
the focus of the present work.
We previously reported that CE-178253 is efficacious
in a model of Parkinsonism [14]. The results suggested
that selective cannabinoid CB1 antagonism may enhance
the antiparkinsonian action of Levodopa and other
dopaminomimetics. We herein report the in vitro and
in vivo quantitative pharmacological evaluation of CE-
178253, a highly selective and potent CB1 receptor
antagonist with inverse agonist properties. Furthermore,
we demonstrate that CE-178253 is efficacious in precli-
nical acute and chronic models of FI, energy expendi-
ture and body weight regulation.
Methods
Reagents
Human CB1 and CB2 receptor cDNAs in pcDNA3 (Invi-
trogen) and/or cell lines were the generous gift of Dr.
Debra Kendall (University of Connecticut). The
sequences of the receptors were confirmed and are the
predominant splice variants. CE-178253 [15], CP-55940
[(1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-
4-(3-hydroxypropyl)cyclohexan-1-ol] were synthesized at
Pfizer Global Research and Development, Groton, CT.
[
3H]CP55,940 (158 Ci/mmol) and GTPg[
35S] were pur-
chased from Perkin Elmer Life Sciences (Boston, MA).
[
3H]SR141716A (44.0 Ci/mmol) was purchased from
Amersham Pharmacia (Piscataway, NJ).
CB1 and CB2 receptors and membrane preparations
HEK293 (CB1)o rC H O( C B 1 and CB2) cells (ATCC)
were stably transfected with the human CB1 or CB2
receptors. Rat brain, and recombinant CB1 and CB2 and
membranes were prepared as described [16]. A Pierce™
BCA kit was used to determine protein concentrations.
Radioligand Binding Assays
Radioligand binding of CE-178253 to CB1 and CB2
receptors were performed as described [14]. CP-178253
was diluted in drug buffer (10% DMSO, and 90% TME
with 5% BSA,) and then 25 μl was added to each well of
a 96-well polypropylene plate. [
3H]SR141716A was
diluted in a ligand buffer (0.5% BSA plus TME) and
25 μl was added to the plate. 10 μg of membranes per
well from human CB1 and CB 2 receptor transfected
cells and rat brain was used in the assay. The plates
were covered and placed in an incubator at 30°C for 60
min. At the end of the incubation period 125 μl of stop
buffer (10% BSA plus TME) was added to the reaction
plate. The plates were then harvested onto GF/C filter
plates (Perkin Elmer Life Sciences) presoaked in BSA
(5 mg/ml) plus TME. Each filter was washed twice with
TME and dried overnight. In the morning the filters
were counted on a Wallac Trilux™ counter.
GTPg[
35S] binding assays at CB1 receptors
GTPg[
35S] binding assays were performed as described
[16]. GTPg[
35S] binding assays were performed in a 96-
well FlashPlate™ format in duplicate using 100 pM
GTPg[
35S] and 10 μg membrane per well in assay buffer
composed of 50 mM Tris HCl (pH 7.4); 3 mM MgCl2
(pH 7.4); 10 mM MgCl2, 20 mM EGTA, 100 mM NaCl,
30 μM GDP, 0.1% BSA and the following protease inhi-
bitors: 100 μg/ml bacitracin, 100 μg/ml benzamidine,
5 μg/ml aprotinin, and 5 μg/ml leupeptin. The assay
mix was incubated with increasing concentrations of
antagonist (10
-10 Mt o1 0
-5 M) for 10 min and chal-
lenged with the cannabinoid agonist CP-55940. Assays
were performed at 30°C for 1 hr. The FlashPlates™ were
then centrifuged at 2000×g for 10 min. Stimulation of
GTPg[
35S] binding was then quantified using a Wallac
Microbeta® [16].
Receptor Occupancy studies
An ex vivo brain receptor occupancy assay was used to
calculate the in vivo receptor occupancy of CE-178253
at selected doses. The inhibition of specific binding of
[
3H]SR141716A was assessed for CE-178253. Brains
were removed from the rats 2 hr after return of food.
Brain homogenates were prepared by adding TME buf-
fer to pre-weighed tissue to obtain a working concentra-
tion of 50 mg/mL, and then homogenizing with a
Polytron for 30 seconds. The homogenate was diluted to
a concentration of 2 mg/mL using TME buffer. For the
receptor occupancy assay, 160 μL of the diluted brain
homogenate was added to the wells of a 96-well poly-
propylene plate, together with 20 μLo ft h er a d i o l i g a n d
[
3H]SR141716A, (final concentration 2.4 nM; diluted
with TME buffer). Triplicate wells were incubated with
20 μL of the cannabinoid agonist CP-55940 (final
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and 10% DMSO) to determine non-specific binding. For
all other wells, 20 μL of TME was added, and these
wells measured total binding. The plates were then cov-
ered and incubated for 90 min at room temperature on
a plate shaker. Reactions were stopped by the addition
of 100 μL ice cold 7.5% BSA in TME. The plates were
aspirated then harvested onto GF/C filter plates (Perkin
Elmer Life Sciences; Boston, MA) using ice-cold TME
buffer. The filter plates had been pre-soaked in 50 μL
0.5% BSA in TME for 60 min. Filters were dried at
room temperature for 30 min, after which 25 μLo f
Microscint™ (Perkin Elmer Life Sciences; Boston, MA)
was added to each and the plates analyzed on a
Microbeta counter. Care was taken in our assay to mini-
mize drug-tissue dissociation by comparing binding in a
time course and under various conditions. The inhibi-
tion of specific [
3H]SR141716A binding was determined
by subtracting the proportion of non-specific binding
relative to total binding. Experiments were run in tripli-
cate with at least an n = 3 for each treatment group.
Plasma CE-178253 measurements
Plasma bound fractions for CE-178253 were determined
using an equilibrium dialysis assay, as previously
described [17]. Spectra-Por 2 membranes (Spectrum
Laboratories Inc., Rancho Dominguez, CA) with a mole-
cular cut-off of 12-14 kDa were used for the dialysis.
Equilibrium of the system was achieved by incubating
the apparatus for 4.5 hr in a 37°C reciprocating water
bath (set at 155 rpm). A standard curve was set up over
the range 1-1000 ng/mL. All samples were quantified
using liquid chromatography/tandem mass spectrometry
using a PE Sciex API 3000 spectrometer. For plasma,
the unbound fraction was determined as the ratio of
concentrations determined in buffer and plasma.
Food intake assays
All animal studies were approved by the Institutional Ani-
mal Care and Use Committee. Male Sprague Dawley rats
on normal chow (8 weeks old, 250-300 g on arrival, 300-
350 g on test day) were obtained from Charles River. After
arrival, animals were individually housed and placed on
powdered rat chow. Rats were maintained on a 12-hr
light/dark cycle and received food and water ad libitum.
In all studies CE-178253 and veh (0.5% methyl cellulose)
administration to rats and mice was by oral gavage.
For the fast-induced re-feeding assay, food was
removed from the cages the afternoon preceding the
test day and the rats were fasted overnight. After the
overnight fast, rats were administered veh. or CE-
178253. Food was reintroduced 30 min after dosing.
Food consumption was measured at selected time points
as indicated in the figures.
For the spontaneous, nocturnal FI assay, rats were
administered veh. (0.5% methyl cellulose) or CE-178253
30 min prior to the start of the dark phase. Food con-
sumption was monitored with electronic scales, and
consumption was recorded every 10 min for 12 hr using
an automated FI system (Columbus Instruments,
Columbus, OH).
Indirect Calorimetry
Whole body oxygen consumption was measured using
an indirect calorimeter (Oxymax from Columbus Instru-
ments, Columbus, OH) in male Sprague Dawley rats.
The rats (300-380 g body weight) were placed in the
calorimetry chambers and the chambers were placed in
activity monitors. All studies were conducted during the
light cycle. Prior to the measurement of oxygen con-
sumption, the rats were fed standard chow ad libitum.
During the measurement of oxygen consumption, food
was not provided to the rats. Basal, pre-dose oxygen
consumption and ambulatory activity were measured
every 10 min for 2.5 to 3 hr. At the end of the basal
pre-dosing period, the chambers were opened and the
animals were administered a single dose of compound
(or veh.) by oral gavage. CE-178253 was prepared in
0.5% methylcellulose as veh. Oxygen consumption and
ambulatory activity were measured every 10 min for an
additional 1-6 hr after dosing. Resting oxygen consump-
tion, during pre- and post-dosing, was calculated by
averaging the 10-min O2 consumption values, excluding
periods of high ambulatory activity (ambulatory activity
count > 100) and excluding the first 5 values of the
pre-dose period and the first value from the post-dose
period. Change in oxygen consumption is reported as
percent and is calculated by dividing the post-dosing
resting oxygen consumption by the pre-dose oxygen
consumption (X 100). VO2,V C O 2, RER and locomotor
activity were all measured.
Four day rat studies
CE-178253 was evaluated in 4-day chow-fed and DIO S-
D rat studies. Male 12-16 week old S-D rats which had
been maintained on regular chow were singly housed
and acclimated to handling and dosing and two days of
food intake were recorded to establish baseline food
intake values before dosing was initiated. The animals
were randomly sorted and assigned to treatment groups
(n = 7-8 per group). Two studies were performed. In
study 1 (age = 12 weeks) the mean starting weight of all
animals was 370 ± 6 g. In study 2 (age = 16 weeks) the
mean starting weight of all animals was 431 ± 11 g. Rats
were dosed (2 mls/kg) with veh. or CE-178253 accord-
ing to body weight. FI and BW were recorded daily.
Male 15 week old S-D rats which had been main-
tained on a high fat diet (Research Diets, D12079BM,
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DIO weight loss study. DIO rats were singly housed
were acclimated to handling and dosing and two days of
food intake were recorded to establish baseline food
intake values before dosing was initiated. The heaviest
animals were randomly sorted and assigned to treatment
groups (n = 8 per group). The mean starting weight of
all animals was 639 ± 8 g. Rats were dosed (2 mls/kg)
with veh. or CE-178253 according to body weight. FI
and BW were recorded daily.
DIO Mouse study
Male, 14 week old C57/Bl6/6J mice which had been
maintained on a high fat diet (45% kcal from fat) for 6
weeks were selected for the DIO weight loss study. The
animals body weights ranged at least 5 standard devia-
tions from age-matched chow-fed control animals mean
b o d yw e i g h t .M i c ew e r es i n g l yh o u s e d .T h em e a ns t a r t -
ing weight of all animals was 38.9 ± 0.5 g. On Day 0,
mice were randomly assigned to treatment groups (n =
10 per group). Mice were dosed daily over 10 days,
starting approximately at 30 minutes before the start of
the 12 hr dark cycle. BW and food intake were recorded
daily.
Calculations and Statistical analyses
All calculations of in vitro receptor characterization
were completed using GraphPad Prism™. Statistical ana-
lyses of in vivo studies were completed using one-way
ANOVA for repeated measures. If the overall result
achieved statistical significance (p < .05), then one-way
ANOVA was employed for each time point and the
results subjected to Fisher’s PLSD (least protected signif-
icant difference). If the conditions of Fisher’s were met,
individual two-tailed T-tests compared the treatment
group to the veh.-only control group for statistical sig-
nificance. p < 0.05 was considered statistically signifi-
cant. Data were excluded from analysis when increased
locomotor activity was recorded. All data shown are the
mean ± standard error of the mean (SEM) except where
noted.
Results
In vitro pharmacology of CE-178253
Radioligand binding
The structure of CE-178253 is displayed in Figure 1.
Saturation and competition radioligand binding assays
were used to characterize membranes prepared from
human recombinant CB1 and CB2 and rat brain mem-
branes. [
3H]SR141716A was used in CB1 and rat brain
membrane binding assays. [
3H]CP-55940 was used in
CB2 binding assays. In membranes prepared from CHO
expressing CB1 receptors, the KD and Bmax of [
3H]
SR141716A were 1.3 nM and 2.3 pmoles/mg,
respectively. In membranes prepared from HEK293
expressing CB1 receptors, the KD and Bmax of [
3H]
SR141716A were 0.9 nM and 1.7 pmoles/mg, respec-
tively. In rat membranes prepared from whole brain the
KD and Bmax of [
3H]SR141716A were 2.1 nM and 3.5
pmoles/mg, respectively. In membranes prepared from
CHO expressing CB2 receptors the KD of and Bmax of
[
3H]CP-55940 were 4 nM and 10 pmoles/mg, respec-
tively. The binding affinities were determined using [
3H]
SR141716A, at CB1 receptors and rat brain membranes
and [
3H]CP-55940 at CB2 receptors. CP-55940 (non-
selective cannabinoid receptor agonist) and SR141716A
(CB1 receptor-selective antagonist) were used in func-
tional assays to characterize the membranes from cells
expressing CB1 and CB2 receptors. Inhibition of CP-
55940-stimulated GTPg[
35S] binding was used to mea-
sure antagonist potency and efficacy at human CB1
receptors expressed in CHO cells. CE-178253 exhibits
both high affinity binding to and functional antagonism
of the human CB1 receptor expressed in Chinese ham-
ster ovary (CHO) cells and rat brain cannabinoid recep-
tors (Table 1).
The binding affinity (Ki) of CE-178253 for the human
CB1 receptor was 0.33 nM (Table 1). Complete inhibi-
tion of [
3H]SR141716A binding was observed at concen-
trations of CE-178253 greater than 10 nM (not shown).
CE-178253 is selective for the human CB1 receptor
subtype over the human CB2 receptor subtype (Ki of
CE-178253 > 10,000 nM), as demonstrated by the
> 30,000-fold difference in the respective binding Ki
values for these two receptor subtypes.
Functional assays
Further in vitro functional profiling demonstrated CE-
178253 to exhibit primarily non-competitive CB1
receptor antagonist properties and to a lesser degree,
competitive antagonism as well. CE-178253 blocked CP-
55940-stimulated GTPg[
35S] binding in a concentration-
dependent manner. CE-178253 (Ki = 0.07 nM) is almost
Figure 1 Structure of CE-178253.
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35S] binding func-
tional assay than in the radioligand binding assay (Ki =
0.33 nM). Schild analysis (Figure 2A-D) in the GTPg
[
35S] assay confirmed a potency similar to that observed
in the binding assays (KB =0 . 6 3n M ,s l o p e=0 . 8 3 ) .T h e
intrinsic efficacy and potency of CP-55940 were both
decreased by increasing concentrations of CE-178253
(Figure 2A) suggesting that CE-178253 appears to
behave as a mixed competitive and non-competitive
antagonist. Inverse agonist potency was weaker than
functional and binding potencies by 29 and 6-fold,
respectively (Figure 2B) [18]. Function of CE-178253
was not assessed at CB2 receptors because of the weak
potency (Ki > 10,000 nM) in binding assays.
Table 1 In vitro pharmacological profile of CE-178253
Competition Binding Assays GTPg[
35S] Functional Assay (human CB1 in CHO cells)
Ki (nM) ± SEM (n) Antagonist Inverse Agonist
Compound Rat brain hCB1 hCB2 Selectivity Ki (nM) IC50 (nM) Intrinsic Activity Slope
CE-178253 0.43 ± 0.13 (5) 0.33 ± 0.07 (5) 15666 ± 6173 (3) > 30,000 0.07 ± 0.01 (5) 2 ± 0.56 (3) 21% 0.83
SR141716A 0.6 ± 0.1 (32) 1.0 ± 0.1 (73) 285 ± 27 (6) 285 0.54 ± 0.2 (25) 3 ± 1 (2) 30% 1
CP-55940 4.2 ± 0.6 (7) 2.9 ± 1.1 (10) 2.0 ± 0.1 (95) 1.5 Agonist ND ND ND
ND, Not determined
The pharmacological properties of CE-178253, SR141716A and CP-55940 were assessed at human CB1, human CB2 receptors and rat brain membranes
(predominantly CB1). The intrinsic activity assessed in inverse agonist assay is the percent decrease in basal GTPg[
35S] binding.
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Figure 2 Functional properties of CE-178253 in GTPg[
35S] binding assays. Panel A. Effect of CE-178253 (0.01 nM-10 μM) on CP-55940
stimulated GTPg[
35S] binding. Panel B. Inverse agonist assay. Panel C. Schild analysis. Panel D. Inhibition of CP-55940 stimulated GTPg[
35S]
binding by CE-178253.
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CE-178253 was tested at 1 μM concentration for binding
affinity at other receptors, ion channels, and uptake sites
(Table 2). CE-178253 did not exhibit any binding activity
(as defined by greater than 50% inhibition at 1 μMC E -
178253) in these assays. Based on these data CE-178253 is
greater than 1000-fold selective over the receptors,
enzymes and channels that were tested. Rimonabant exhi-
bits weak agonist activity at the putative third cannabinoid
receptor GPR55 [19] with an EC50 approximately 500-fold
lower than that observed at CB1 receptors. No agonist
activity was detected with 10 μM CE-178253 at GPR55.
Rimonabant also binds weakly to the Vanilloid 1 (TRPV1)
receptor channel [20]. TRPV1 was inhibited by 11% (range
= 9-13%, n = 2) by 10 μM CE-178253. These data suggest
that CE-178253 does not interact with either TRPV1 or
GPR55. CE-178253 was not evaluated against TRPM8.
Rimonabant has been reported to bind to TRPM8 [21].
In vivo pharmacology of CE-178253
As previously reported, CE-178253 dose-dependently
reversed the effects of the centrally acting cannabinoid
agonist CP-55940 in all four components of the tetrad
[14], confirming pharmacological antagonism of central
CB1 receptor-driven responses.
Determination of plasma concentration/effect relationships
and brain receptor occupancy of CE-178253 in acute food
intake assays
The in vivo pharmacology of CE-178253 was evaluated
using two models of acute FI: 1) a spontaneous
nocturnal feeding paradigm and, 2) an overnight fast-
induced refeeding paradigm. Quantitative pharmacology
was used to establish concentration/effect relationships
based on unbound efficacious plasma concentrations,
receptor occupancy and FI efficacy.
The first FI model used for determining anorectic effi-
cacy of CE-178253 was spontaneous nocturnal feeding
in rats. In rodents, most feeding activity takes place dur-
ing the dark phase (nocturnal feeding cycle). In this
model, male S-D rats were orally administered com-
pound 30 min prior to the onset of the nocturnal phase.
CE-178253 dose-dependently inhibited spontaneous
nocturnal FI (0.3 mg/kg, 1 mg/kg and 3 mg/kg, p.o., Fig-
ure 3A and 3B) as compared to veh.-treated rats. Cumu-
lative FI was significantly inhibited (p < 0.05) at each
hourly time point throughout the dark phase period at
each dose tested except at the 0.3 mg/kg dose at the
one hr time point (Figure 3A). In addition, the effect of
treatment on hourly FI was also assessed. With the
exception of the 0.3 mg/kg 0-1 hr interval, CE-178253
(all doses) treatment resulted in a statistically significant
decrease in FI through the first four hr compared to
veh. No other time points in the interval analysis reach
statistical significance. A concentration effect relation-
ship analysis comparing FI reductions to unbound
plasma concentrations (Cave, fu, p, 0-2.5 hr) using the
cumulative FI at 2.5 post dose confirmed a concentra-
tion-dependent reduction in FI wherein the unbound
EC50 was calculated to be 0.5 nM (Figure 3B). A 25%,
84% and 94% decrease in FI at the three doses (0.3, 1,
Table 2 Receptors, ion channels, and uptake sites measured for CE-178253 binding activity
Receptors Ion Channels/Regulatory sites Uptake sites
Adenosine (A1,A 2a,A 3) Calcium channels: Choline
Adrenergic (a1, a2, b1, b2) L-type DHP Dopamine
Angiotensin-II (AT1,A T 2) L-type (diltiazem) GABA
Benzodiazepine L-type (verapamil) 5-HT
Bradykinin (B1,B2) N-type Norepinephrine
Dopamine (D1, D2, D3, D4)
GABA (non-selective) Functional Assays
Glutamate (AMPA, kainate, NMDA) GPR55 (no activity at 10 μM)
Histamine (H1,H 2,H 3) TRPV1 (11% inhibition at 10 μM)
5-Hydroxytryptamine (5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT7)
Melanocortin (MC4)
Muscarinic (M1,M 2,M 3,M 4)
Nicotinic (neuronal, muscle)
Opiate (delta, kappa, mu)
Platelet activating factor
Steroid (glucocorticoid)
Tachykinin (NK1)
Thyroid hormone
Vasopressin (V1,V 2)
Inhibition CE-178253 was evaluated for inhibition of binding to the following receptors, channels and sites at 1 μM concentration (except where noted).
CE-178253 did not inhibit binding by > 50% at any site noted in the panel.
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observed. Cumulative food intake at the 2.5 hr time
point was 3.2 ± 0.3, 2.4 ± 0.2, 0.5 ± 0.1 and 0.2 ± 0.1 in
the veh, 0.3 mg/kg, 1 mg/kg, 3 mg/kg treated rats,
respectively.
Administration of CE-178253 to male S-D rats inhib-
ited overnight fast-induced refeeding. S-D rats were
fasted overnight and veh. (0.5% methylcellulose; MC) or
CE-178253 was administered orally. Food was provided
to the rats 30 min after dosing. Food intake was mea-
sured 30 min and 2 hr after return of food. Dose- and
unbound plasma concentration-dependent decreases in
cumulative FI versus veh. were observed (Figure 4A, B,
Table 3) at both time points after return of food. How-
ever, the efficacy (as a percent) was greater in the 0.5-2
hr interval than in the first 0.5 interval. In contrast, FI
efficacy in the dark-phase feeding was consistent
throughout the first four hr (Figure 3B).
Brain CB1 receptor occupancy by CE-178253, as esti-
mated by ex vivo binding, was also dose-dependent
(Table 3). The ratios of unbound plasma and total
plasma to unbound brain and total brain concentrations
were determined at four doses (0.3, 1, 3, 10 mg/kg, p.o.)
to assess the brain impairment of CE-178253. This ana-
lysis is a useful predictor of the free brain concentration
of drugs ([22], [23], [24]). The mean ( ± SD, n = 3 for
each dose) of the ratios was 2.9 ± 0.25 suggesting that
this compound exhibits, little, if any brain impairment.
Rimonabant exhibits a rati ob e t w e e n1a n d2( d a t an o t
shown). These data suggest that a minimum of a 3-fold
coverage of the Ki (calculated 50-75% receptor occu-
pancy and brain/plasma ratios) appears to be required
for maximal food-intake reduction.
Determination of plasma concentration/effect relationships
of CE-178253 in indirect calorimetry studies
Indirect calorimetry studies measuring oxygen consump-
tion demonstrated that CE-178253 increases energy
expenditure (Figure 5). Oral administration of CE-
178253 at 1 mg/kg or 3 mg/kg increased average oxygen
consumption in S-D rats by 28% and 39%, respectively,
between 1 and 3 hr after dosing. No differences in oxy-
gen consumption of veh.-treated or CE-178253 treated
rats were observed in the first 1 hr after dosing (Figure
5). These data are consistent with the tmax of 1 hr that
is observed in rats given oral CE-178253 (data not
shown). The respiratory quotient (a measure of sub-
strate oxidation) declined from 0.85 to 0.75 over the
first hr suggesting a shift from carbohydrate to fat oxi-
dation. A non-statistically significant (p > 0.05) increase
in locomotor activity was also observed in all treatment
groups. Though the two studies cannot be compared
directly the efficacious unbound plasma concentrations
(normalized to Ki) were similar in both FI and indirect
calorimetry studies (Tables 3 and 4).
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Figure 3 Effect of CE-178253 in S-D rats on nocturnal phase
feeding in spontaneous FI model. 3A. Time and dose-response
relationship of food intake efficacy of CE-178253. S-D rats were
administered veh. (0.5% MC), 0.3, 1 or 3 mg/kg CE-178253 p.o. 30
min prior to the onset of the dark phase feeding cycle. Food was
returned 30 min later and cumulative food consumption was
measured for 12 hr. Data shown are the Mean +/- SEM, n = 8/
group. All time points were statistically significantly different from
veh. (p < 0.05) except for the 0.3 mg/kg one hr time point. 3B.
Effect of CE-178253 on hourly food intake in S-D rats on
nocturnal phase feeding in spontaneous FI model. S-D rats were
administered veh. (0.5% MC), 0.3, 1 or 3 mg/kg CE-178253 p.o. 30
min prior to the onset of the dark phase feeding cycle. Food was
returned 30 min later and hourly food consumption was measured
for 12 hr. Data shown are the Mean +/- SEM, n = 8/group. All dose
groups were statistically significantly different from veh. (p < 0.05) at
2-5 hr time intervals. In addition, the 1 and 3 mg/kg dose groups
were statistically significantly different from veh. (p < 0.05) at the 1
and 6 hr time points. 3C. Concentration-effect relationship for
CE-178253 in the spontaneous FI model at 2.5 hr post-dose.S -
D rats were administered veh. (0.5% MC), 0.3, 1 or 3 mg/kg CE-
178253-01 p.o. 30 min prior to the onset of the dark phase feeding
cycle. Food was returned 30 min later and cumulative food
consumption was measured for 2 hr. The EC50 corresponds to a
50% reduction at 2 hr after the start of the dark cycle feeding
phase. Each data point represents the mean of three animals. * = p
< 0.05 vs. veh.
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Page 7 of 13In a separate study, core body temperature was mea-
sured in C57BL/6J mice. Core body temperature and
was found to be increased at the 1 and 3 mg/kg doses
by 0.7 ± 0.3 and 1.2 ± 0.3°C (n = 5 per group) compared
to veh, respectively.
Weight loss efficacy of CE-178253
Chow-fed, lean rats and two animals of obesity, DIO rat
and DIO mouse, were used to evaluate body weight
changes in response to CE-178253 treatment. A preli-
minary four day study was performed in chow-fed and
DIO rats and followed up with a ten day study in DIO
mice.
DIO rats were treated once daily with veh. (0.5% MC)
or CE-178253 at doses of 0.3 mg/kg p.o. or 1 mg/kg p.o.
in a 4-day study (Figures 6A and 6B). CE-178253 dose-
dependently reduced daily FI (Figure 6A). The effects on
FI were apparent after the first doses and sustained over
t h e4 - d a ys t u d yp e r i o d .A l o n gw i t ht h es i g n i f i c a n t
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Figure 4 Effect of CE-178253 in fast-induced refeeding food
intake model. 4A. Dose- and time-dependent effects on
cumulative FI in S-D rats by oral administered CE-178253 in
the fast-induced refeeding model. Overnight fasted S-D rats were
given veh. (0.5% MC) or 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg
CE-178253 p.o. in 0.5% MC. Food was returned 30 min after dosing
and cumulative food consumption was measured at the 2 hr time
point. The number of animals was 8-11 in the veh. and CE-178253
treated groups. Veh.-treated rats ate 8.2 ± 0.3 grams chow. The
reduction in FI ± SEM in grams/rat is displayed. * = p < 0.05 vs. veh.
4B. concentration-effect relationship for CE-178253 in the
fasted-induced refeeding FI model. The unbound plasma
concentration of CE-178253 was measured at 2.5 hr post-dose. The
EC50 corresponds to a 35% reduction at two hr post-dose which
corresponds to a maximal FI reduction of 70% in this model.
Table 3 FI, receptor occupancy, plasma exposure in S-D rats administered CE-178253
Dose (mg/kg,
p.o.)
Food Intake % decrease
(mean ± SEM)
% Receptor Occupancy
(mean ± S-D)
Unbound Plasma Concentration
(nM ± S-D )
Unbound plasma/rat
brain Ki
0.3 6 ± 3 27 ± 12 0.17 ± 0.02 0.4
1 25 ± 11 64 ± 2 1.0 ± 0.3 2.3
3 62 ± 5.2* 78 ± 6 2.7 ± 1.0 6.2
10 75 ± 6.2* 82 ± 2 15.6 ± 1.6 36
*significantly different from veh. p < 0.05
Overnight fasted S-D rats were administered veh. (0.5% MC), or CE-178253-01 p.o. Food was returned 30 min later. Cumulative food consumption was measured
2 hr after the return of food.
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Figure 5 Stimulation of acute energy expenditure by CE-
178253. Male S-D rats were given veh. (0.5% MC), 1 mg/kg or 3
mg/kg CE-178253 (p.o.). Energy expenditure, measured by indirect
calorimetry, was measure for 2 hr before dosing and 4 hr after
dosing. The mean ± SEM (n = 8/group) is displayed. * = p < 0.05
vs. veh.
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Page 8 of 13anorectic effect in DIO rats, CE-178253 significantly and
dose-dependently reduced body weight over the 4-day
study period (Figure 6B). A 3.3% and 5.9% decrease in
body weight was observed at the 0.3 and 1 mg/kg doses
compared to veh, respectively. In contrast, there was no
change in weight in veh-treated rats. Initial and final
body weights of veh-treated rats were 643 ± 15 g and
645 ± 14 g, respectively. Initial and final body weights of
0.3 mg/kg CE-178253-treated rats were 632 ± 11 g and
616 ± 12 g, respectively. Initial and final body weights of
1 mg/kg CE-178253-treated rats were 637 ± 11 g and
602 ± 11 g, respectively. A statistically significant differ-
ence in BW between veh and the 1 mg/kg dose was
observed (p < 0.05).
CE-178253 was also evaluated in chow-fed rats in a
4 day FI and BW study. Rats were treated once daily with
veh. (0.5% MC) or CE-178253. In the first study the same
doses used in the DIO study were used to compare FI
and BW efficacy. In contrast to the 4 day rat DIO study
the effects of FI and BW were modest suggesting that
CE-178253 is more efficacious in DIO than chow-fed rats
(data not shown). CE-178253 was clearly efficacious in
acute food intake studies in chow-fed rats up to 12 hours
(Figure 3). A comparison of 24 hr FI in chow-fed and
DIO rats yielded different efficacy in response to CE-
178253 treatment. The 1 mg/kg dose yielded an 8%
decrease in 24 hr FI compared to veh-treated animals (p
= 0.053). CE-178253 reduced daily FI only on Day 1 in
the high dose group whereas significance was observed in
the DIO rat study with both low and high doses (Figure
6A). No statistically significant differences in BW changes
were observed in the 0.3 and 1 mg/kg dosing groups.
Initial and final body weights of veh-treated rats were
371 ± 7 g and 390 ± 7 g (n = 8), respectively. Initial and
final body weights of 0.3 mg/kg CE-178253-treated rats
were 374 ± 7 g and 388 ± 9 g, respectively. Initial and
final body weights of 1 mg/kg CE-178253-treated rats
were 373 ± 7 g and 390 ± 9 g, (respectively.
Based on the weak efficacy observed at the 0.3 and 1
mg/kg doses the study was repeated using higher doses
of CE-178253 (Figures 7A and 7B). At 3 and 10 mg/kg
(QD, p.o.) doses, statistically significant decreases in FI
and BW were observed. Initial and final body weights of
veh.-treated rats were 435 ± 11 g and 451 ± 12 g (n =
8), respectively, a 9% gain in BW. Initial and final body
weights of 3 mg/kg CE-178253-treated rats were 436 ±
9 g and 427 ± 9 g, respectively, a 2% decline. Initial and
Table 4 Oxygen consumption, Respiratory Quotient, and unbound plasma exposure in S-D rats administered
CE-178253
Dose (mg/kg, p.o.) VO2, ave, 1-3 hr
( ± S-D)
Respiratory Quotient
(VCO2/VO2)
Unbound Plasma Concentration
(nM ± S-D )
Unbound plasma/rat brain
CB1 RK i
Veh. 3 ± 5 0.85 ± 0.03 NA NA
1 28 ± 7* 0.74 ± 0.02* 0.8 ± 0.2 1.8
3 39 ± 5* 0.75 ± 0.03* 3.8 ± 0.9 8.8
*significantly different from veh. p < 0.05
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Figure 6 Effect of CE-178253 on FI (6A) and BW (6B) in DIO
rats. FI and BW were measured in DIO rats (weight = 643 ± 15 g
(Veh.), 632 ± 11 (0.3 mg/kg CE-178253) 637 ± 11 (1 mg/kg CE-
178253); mean ± SEM, n = 8/group) daily after once daily
administration of veh. (0.5% MC) or CE-178253 at either 0.3 mg/kg
or 1 mg/kg p.o. FI data shown are the total amount of food
consumed expressed in energy grams consumed for each day of
treatment. The mean ± SEM (n = 8/group) is shown. * = p < 0.05
vs. veh.
Hadcock et al. BMC Pharmacology 2010, 10:9
http://www.biomedcentral.com/1471-2210/10/9
Page 9 of 13final body weights of 10 mg/kg CE-178253-treated rats
were 435 ± 11 g and 430 ± 10 g, respectively, 1%
increase. As such, the two high dose CE-178253 groups
of prevented weight gain that was observed in the veh.-
treated rats. These data suggest that efficacy can be
maintained but require a higher dose in chow-fed rats.
In PK studies, no differences in exposure were observed
between chow-fed and DIO rats. Thus, as has been
reported for other CB1 receptor antagonists it is likely
that DIO rats are more sensitive to the anorectic and
weight loss effect of CE-178253.
DIO mice were treated once daily with veh. (0.5% MC)
or CE-178253 at 1 mg/kg or 3 mg/kg, p.o., in a 10-day
study (Figures 8A and 8B). CE-178253 significantly and
dose-dependently reduced FI over the 10-day study. The
lower dose of CE-178253 (1 mg/kg, p.o.) provided for a
non-significant 8% reduction in FI, whereas the 3 mg/kg
dose led to a significant 31% reduction in cumulative FI.
As with other CB1 receptor antagonists, the food intake
reduction was maximal over the first five days and
declined over time (Figure 8A). However, FI reductions
were still evident on the final day of dosing at the high
dose. Along with the anorectic effect in DIO mice, CE-
178253 significantly and dose-dependently reduced body
weight over the 10-day study period (Figure 8B). The
high dose group (3 mg/kg) lost, on average 18% BW.
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Figure 7 Effect of CE-178253 on FI (7A) and BW (7B) in chow-
fed rats. FI and BW were measured in chow-fed rats, treated after
once daily administration of veh. (0.5% MC) or CE-178253 at either 3
mg/kg or 10 mg/kg p.o. Initial and final body weights of veh-
treated rats were 435 ± 11 g and 451 ± 12 g (n = 8), respectively.
Initial and final body weights of 3 mg/kg CE-178253-treated rats
were 436 ± 9 g and 427 ± 9 g, respectively. Initial and final body
weights of 10 mg/kg CE-178253-treated rats were 435 ± 11 g and
430 ± 10 g, respectively. FI data shown are the total amount of
food consumed expressed in grams for each day of treatment. The
mean ± SEM (n = 6-8/group) is shown. * = p < 0.05 vs. veh.
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Figure 8 Effect of CE-178253 on FI (8A) and BW (8B) in DIO
mice. FI and BW were measured in DIO mice (baseline body weight
= 38.8 ± 0.7 g (Veh.), 38.7 ± 0.6 (1 mg/kg CE-178253) 38.8 ± 0.6 (3
mg/kg CE-178253); mean ± SEM, n = 10/group) daily after once
daily administration of veh. (0.5% MC) or CE-178253 at either 1 mg/
kg or 3 mg/kg p.o. FI data shown are the total amount of food
consumed expressed in grams consumed for each day of treatment.
The mean ± SEM (n = 10/group) is shown. * = p < 0.05 vs. veh.
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Endocannabinoids and their receptors are involved in
various centrally and peripherally mediated physiological
functions including modulation of appetitive behavior,
energy metabolism and energy balance [25]. Further-
more, endocannabinoids are elevated in obese humans
and rodent models of obesity [26], suggesting a link
between an activated endocannabinoid system and obe-
sity. The beneficial effects of pharmacological antagon-
ism of the endocannabinoid system to the treatment of
human obesity is well supported by pre-clinical experi-
ments and, more directly, the results of human clinical
trials with rimonabant have been shown to be effective
in achieving weight loss in long-term studies in humans
[27]. In the present study, we have described the in vitro
and in vivo pharmacology of a novel, selective, and
orally active mixed competitive and non-competitive
CB1 cannabinoid receptor antagonist identified as CE-
178253.
Cannabinoid receptors selectively couple to the Gi
family of G proteins [1]. CE-178253 displayed a high
affinity for CB1 receptor binding (0.33 nM), and func-
tional antagonism (0.07 nM) that was highly selective (
> 30,000-fold) compared to CB2 receptors. These in
vitro pharmacological properties, along with the
observed lack of activity ( > 50% inhibition of binding at
1 μM CE-178253) at a select panel of receptors,
enzymes and ion channels, clearly indicate the desired
pharmacological properties of a CB1 receptor antagonist
as present in CE-178253. SR141716A (rimonabant) was
initially considered to be a silent antagonist (i.e., the
compound had no intrinsic activity), however studies
have reported hyperalgesic, stimulant and immunosup-
pressive effects of this compound, suggesting that it may
be an inverse agonist in vivo. In support of these find-
ings, rimonabant has been reported to decrease basal
CB1 receptor signaling in addition to antagonism of ago-
nist-mediated responses [18]. Our GTPg[
35S] binding
results with CE-178253 further demonstrate that it is
also a weak inverse agonist (relative to the antagonist
Ki) in vitro at the CB1 receptor. The intrinsic inverse
agonist potency of CE-178253 is higher than the effica-
cious unbound plasma concentration. These data sug-
gest that the observed in vitro inverse agonist efficacy of
CE-178253 is not critical for efficacy. However, discrimi-
nation between inverse agonism endocannabinoid tone
in vivo is difficult. Apparent inverse agonism in vivo
may be due to high endocannabinoid tone.
In our pre-clinical assessment of CE-178253, we have
shown that the compound is efficacious in two models
of FI, fast-induced refeeding and spontaneous, nocturnal
FI. Efficacy in both of these models provides evidence
that the compound has significant anorectic activity in
rodents consistent with its binding affinity. CE-178253
appears to be more efficacious in spontaneous feeding
vs. fast-induced refeeding. While robust inhibition of FI
efficacy was observed in both models, direct comparison
to previous studies is difficult. For example, Kirkham
et al [28] examined the effect of SR141716A on 2-AG-
mediated hyperphagia. The dose of SR141716A used
(0.5 mg/kg) in this pharmacological challenge attenuated
FI by ~50%. These data are similar to our results in the
fast-induced refeeding model where it has been reported
that hypothalamic 2-AG levels are high after a fast.
In addition to anorectic efficacy, CB1 receptor antago-
nists also increase energy expenditure (reviewed in 10).
A comparison of the quantitative pharmacology between
FI and energy expenditure suggest a similar concentra-
tion/effect relationship for the two endpoints. The rela-
tive contribution, however, of central and peripheral
CB1 receptors as well as target tissues (muscle or brown
adipose) in modulating energy expenditure remains to
be elucidated.
Rimonabant [7,29-31] and AM-251 [32], a CB1 recep-
tor antagonist structurally similar to rimonabant) treat-
ment decreased body weight in chronic studies in both
normal and obese rodents. DIO rodents appear to be
more sensitive to the anorectic efficacy of CB1 receptor
antagonists. Like other CB1 receptor antagonists, sus-
tained weight loss was observed with CE-178253 treat-
ment in both DIO rats and DIO mice. In PK studies, no
differences in exposure of CE-178253 were observed
between chow-fed and DIO rats. However, the FI and
BW efficacy the 4 day study in chow-fed rat study
required a much higher dose to achieve equivalent effi-
cacy compared to the DIO rats suggesting that CE-
178253 is more potent in DIO than chow-fed rats.
Conclusions
As with all CB1 receptors antagonists the relative contri-
butions of FI and energy metabolism to weight loss
remains to be determined. None of the above referenced
studies provided any quantitative in vivo pharmacologi-
cal analysis. One of the most critical components of
increasing confidence in mechanism is the establishment
of in vitro vs. inv i v oconcentration effect relationships.
The complexities in the understanding of these relation-
ships will vary depending on the stage and available che-
mical lead matter of a drug discovery program. These
can range from concentration/effect relationships in
early stage discovery projects to true PK/PD relation-
ships at the later stages of discovery and into develop-
ment (Scott et al, manuscript in preparation). We
sought to better understand the concentration/effect
relationships of CE-178253 by comparing unbound
plasma concentrations, brain receptor occupancy, bind-
ing affinity and FI efficacy. Unbound plasma
Hadcock et al. BMC Pharmacology 2010, 10:9
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Page 11 of 13concentrations normalized to Ki provided a useful
benchmark for comparing compounds across different
in vivo studies and facilitated early predictions of effica-
cious human plasma concentrations (Scott, DO et al,
manuscript in preparation). Surprisingly, very little data
exist on the in vivo quantitative pharmacology of CB1
receptor antagonists, a therapeutically important target
class. Most studies have relied on dose and not unbound
plasma concentrations were not reported. Fong et al
[33] assessed weight loss efficacy in relation to receptor
occupancy. They reported that a minimum of 30%
receptor occupancy in a 14 day weight loss study was
required to achieve measurable weight loss. It is likely
that endogenous cannabinoid levels are high after the
fast in the FI studies but not in the indirect calorimetry
studies. Thus, a lower concentration of compound could
be required for maximal efficacy when assessing energy
expenditure compared to FI.
We did not observe changes in FI at this level of
receptor occupancy under the standard study conditions.
However, CE-178253 reaches steady-state between brain
and plasma at a slower rate than other CB1 receptors
antagonists including rimonabant (data not shown).
When the interval between dosing to return of food was
extended to 2 hr from 30 min, a statistically significant
reduction in FI (27% ± 6, p < 0.05) at 50% receptor
occupancy was observed. This efficacy is similar to that
observed with other CB1 receptor antagonists. For maxi-
mal weight loss efficacy, 60-90% receptor occupancy is
required for taranabant similar to our observations with
CE-178253 receptor occupancy studies.
While brain receptor occupancy studies are in them-
selves very important, CB1 receptor antagonists have
pronounced peripheral metabolic effects that appear to
be independent of the CNS effects [34]. Having mea-
surements of both brain and unbound plasma concen-
tration provides views of multiple sites of action. These
include possible direct effects on adipose, liver, pancreas
and muscle, all tissues that are involved in maintaining
energy balance [35].
In summary, we have linked in vitro (binding and
functional), ex vivo (brain receptor occupancy) and in
vivo (unbound plasma concentrations) to define the
quantitative pharmacology and concentration/effect rela-
tionships preclinical models of food intake and energy
expenditure with the novel CB1 receptor antagonist, CE-
178253.
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